Morphic Holding is a biopharmaceutical company that develops oral small-molecule integrin therapeutics for autoimmune, cardiovascular, metabolic diseases, fibrosis, and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor in Phase 1 clinical trial for inflammatory bowel disease, and avß6 for fibrotic diseases. The company has collaborations with Engitix, Schrödinger, AbbVie Biotechnology, and Janssen Pharmaceuticals. Morphic Holding was founded in 2014 and is based in Waltham, Massachusetts.